About this episode

Dr. Tara Gregory and Dr. Jay Spiegel discuss the evolving role of CAR T-cell therapy in lymphoma and myeloma, covering patient selection, toxicity management, and future directions.

Tara Gregory, MD, Colorado Blood Cancer Institute, Denver, CO and Jay Spiegel, MD, Sylvester Comprehensive Cancer Center, Miami, FL Recorded on May 28, 2026 Tara Gregory, MD President Colorado Blood Cancer Institute Denver, CO Jay Spiegel, MD Assistant Professor Division of Transplant and Cellular Therapy University of Miami Sylvester Comprehensive Cancer Center Miami, FL In this episode, Dr. Tara Gregory from the Colorado Blood Cancer Institute, and Dr. Jay Spiegel from the Sylvester Comprehensive Cancer Center discuss the evolving role of CAR T-cell therapy in lymphoma and myeloma. They provide a practical overview of CAR-T, including currently approved indications, importance of early referral, patient selection considerations, and strategies for engaging patients in treatment discussions. The conversation also covers key aspects of toxicity management and post-treatment monitoring, while addressing current limitations of CAR-T therapy and future directions that may further expand its role in patient care. Tune in today for this exciting episode! Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer…

Sponsors

Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Kite, a Gilead Company

More episodes of Treating Blood Cancers

• Waldenström macroglobulinemia: What to Know in Practice · July 10, 2026 · 36 min
• Mastocytosis: What Clinicians Need to Know · June 25, 2026 · 34 min

Explore listener stats, chart rankings, contacts and more on the Treating Blood Cancers podcast page.